US FDA expands GSK's RSV vaccine approval to adults aged 50 to 59
By Sriparna Roy & Christy Santhosh
Senator slams GlaxoSmithKline over pricey inhaler for children
By Dan Diamond & Aaron Gregg
FDA approves GSK's RSV vaccine for high-risk adults ages 50 to 59, expanding shot's reach
By Annika Kim Constantino
GSK raises $1.5 bln from sale of remaining Haleon stake
By Prerna Bedi, Jane Merriman & Varun HK
GSK shares tumble 9% after 70000 Zantac lawsuits allowed to proceed
By Maggie Fick & Yadarisa Shabong
GSK intends to sell its remaining stake in Haleon
By Anchal Rana, Shailesh Kuber & Shilpi Majumdar
GSK Nigeria calls an end to its business, to return cash
By Chijioke Ohuocha
GlaxoSmithKline Pulls Back Inhaler Patents After US FTC Warning Letter
By Leah Nylen & Nacha Cattan
Former GSK building in Navy Yard fails to sell at sheriff's sale
By Paul Schwedelson
GSK raises $1.24 bln from latest Haleon stake sale
By Anchal Rana & Muhammad Tasim Zahid
GSK to cut US prices for Advair, Valtrex and Lamictal
By Michael Erman & Jonathan Oatis
Goldman Sachs neutral on GlaxoSmithKline stock By Investing.com
By Ahmed Abdulazez Abdulkadir
GSK's cancer drug combination meets primary goal in late-stage trial
By Sonia Cheema & Aby Jose Koilparambil
GSK boosts respiratory portfolio with $1.4 bln Aiolos Bio deal
By Eva Mathews & Jason Neely
GSK CEO says RSV vaccine revenue to top 1 bln pounds in first year
By Josephine Mason & Michele Gershberg
GSK completes acquisition of Aiolos Bio for up to $1.4 bln
By Jason Neely & Pablo Mayo Cerqueiro
No Change to GSK Shares' Fair Value Estimate Despite Litigation Risk
By Christopher Johnson
GSK joins AstraZeneca, Boehringer in capping US out-of-pocket inhaler prices at $35 per month
By Zoey Becker
GSK's blood cancer drug meets primary goal in late-stage trial
By Eva Mathews, Sharon Singleton & Janane Venkatraman
Pharma giant GSK plunges 9% after U.S. court allows scientific testimony in Zantac lawsuits
By Jenni Reid
GSK's blood cancer drug meets main goal in late-stage trial; analysts tout comeback
By Shailesh Kuber & Yadarisa Shabong
GSK's injectable HIV drug shows promise over daily pills
By Eva Mathews & Dhanya Ann Thoppil
GSK's India unit posts Q2 profit rise on strong vaccine demand
By Ashna Teresa Britto & Nivedita Bhattacharjee
India's GlaxoSmithKline Pharma posts rise in Q1 profit on steady vaccine business
By Kashish Tandon & Sohini Goswami
GlaxoSmithKline (GSK) secures SEC approval to delist from NGX
By Agbetiloye Adekunle
GlaxoSmithKline Agrees to Pay $3 Billion in Fraud Settlement
By Katie Thomas & Michael S. Schmidt
Biting The Data Management Bullet At GlaxoSmithKline
By Thomas H. Davenport
GSK soothes investors by settling first Zantac cancer lawsuit due for US trial
By Eva Mathews & Natalie Grover
GSK Shares Dive as Litigation Woes Deepen
By Christopher Johnson
FDA pulls authorization for GSK-Vir's COVID therapy as BA.2 cases rise
By Leroy Leo, Shounak Dasgupta & Bhanvi Satija
FDA approves United States' first-ever RSV vaccine
By Oriana Gonzalez
23andMe's Pharma Deals Have Been the Plan All Along
By Megan Molteni
GSK shares drag the FTSE 100 as company faces muli-billion pound bill after Zantac trial ruling
By Elliot Gulliver-needham & Rupert Hargreaves
GlaxoSmithKline fined $490m by China for bribery
By Carrie Gracie
GlaxoSmithKline Pharma Q3 Results | Net profit slumps 72%, revenue flat at ₹805 crore
By Jomy Pullokaran